Presently, RT combined with immune checkpoint inhibitors (such as PD-1 antibody or CTLA-4 antibody) has been shown to induce about 29% rate of abscopal effect in patients with advanced tumors; nevertheless, the incidence of abscopal effect is still unsatisfactory, which may be caused by lack of tumor infiltrating activated T cells and further make it impossible to initiate an adequate immune response (Ozpiskin et al, 2019; Zhao and Shao, 2020). Here, CTLA4 is linked to neoplasm.